Ceryx Medical, a revolutionary business behind a unique bioelectronic technology that could change the way diseases such as heart failure are treated, is a finalist in the Best Early Stage Medtech category; and EnsiliTech, a biotechnology start-up developing ensilication, a platform technology, to remove the need for refrigeration when transporting and storing biologicals such as vaccines, is a finalist for the Best Startup Biotech award.

The annual OBN Awards, now in their 15th year, are a highly regarded and sought-after awards programme for the Life Sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the industry.

Alain Nogaret, Founder of Ceryx Medical which spun-out with the University of Bristol, and Professor of Condensed Matter Physics at the University of Bath, says:

I am delighted that the novel cardiac pacing technology developed by Ceryx Medical is being recognized by experts from the Life Science industry through this shortlisting for an OBN award.

Twelve award categories shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical needs, outstanding company progression and the delivery of real-life, tangible results.

Asel Sartbaeva, co-Founder and CEO of Ensilitech says:

We are honoured to be among the finalists for this award, which reflects our dedication to creating cutting-edge biotechnology that can address some of the most pressing challenges of our time. We would like to thank our team, our partners, and our customers for their support and trust in our vision.

The winners will be announced at the OBN Awards Ceremony on 22 November at The Royal Lancaster Hotel, London.